首页|经典中药复方和单体治疗慢性阻塞性肺疾病研究进展

经典中药复方和单体治疗慢性阻塞性肺疾病研究进展

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
慢性阻塞性肺疾病(COPD)是一种不可逆的异质性肺部疾病,具有较高的患病率和死亡率.临床治疗多采用支气管扩张剂,抗炎药物等,但预后较差且不良反应大.中药复方以其独特的辨证体系、灵活的配伍以及安全有效的特点已被用作治疗COPD的一种方案,可通过"多成分-多靶点-多通路"干预疾病.研究发现,在众多调控COPD的通路中,白细胞介素-17(IL-17)信号通路中衔接蛋白核因子κB激活剂1(Act1)通过信号转导复合体IL-17R-Act1-肿瘤坏死因子受体相关因子6(TRAF6)-核因子κB抑制蛋白激酶(IKK)激活下游核因子κB(NF-κB)等信号通路中新的调控机制,是COPD发生和发展的主要通路之一,能够特异性地调控炎症反应、氧化应激反应、气道重塑等,从而起到干预COPD的作用.因此,对经典中药复方和单体调控IL-17信号通路治疗COPD的作用机制进行系统阐述并总结其研究进展,以期为精准化防治COPD提供参考.
Research Progress on Classic Chinese Medicine Compounds and Monomers in the Treatment of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease(COPD)is an irreversible and heterogeneous lung disease with high morbidity and mortality.Clinical treatments often include bronchodilators and anti-inflammatory drugs,but the prognosis is poor and the side effects are significant.Chinese medicine compounds,with their unique syndrome differentiation system,flexible combinations,and safe and effective characteristics,have been used as a treatment option for COPD.These compounds can intervene in the disease through a"multi-component,multi-target,multi-pathway"approach.Research has shown that among the numerous pathways regula-ting COPD,the interleukin-17(IL-17)signaling pathway plays a major role in the occurrence and development of COPD.In this pathway,the adaptor protein nuclear factor-κB activator 1(Act1)forms a signal transduction complex with IL-17R,Act1,tumor necrosis factor receptor-associated factor 6(TRAF6),and IκB kinase(IKK),activating downstream nuclear factor-KB(NF-κB)and other signaling pathways.This specific regulatory mechanism can modulate inflammatory responses,oxidative stress responses,and airway remodeling,thereby intervening in COPD.Therefore,this study systematically elucidated and reviewed the mechanisms of classic Chinese medicine compounds and monomers in regulating the IL-17 signaling pathway in the treatment of COPD,aiming to provide valuable references for the precise prevention and treatment of COPD.

Chinese medicine compoundChinese medicine monomerChronic obstructive pulmonary diseaseInterleukin-17 sig-naling pathwaySignal transduction complexMechanism of actionResearch progressReview

史艳丽、王云超、杨震、李宏娥、魏雪艳、王新华

展开 >

甘肃中医药大学公共卫生学院,兰州,730000

甘肃中医药大学基础医学院,兰州,730000

中药复方 中药单体 慢性阻塞性肺疾病 白细胞介素-17信号通路 信号转导复合体 作用机制 研究进展 综述

国家重点研发计划"精准医学研究"重点专项中央引导地方科技发展资金项目2022年甘肃省高等学校产业支撑计划项目

2017YFC090720222ZY1QA0032022CYZC-53

2024

10.3969/j.issn.1673-7202.2024.11.026

世界中医药
世界中医药学会联合会

世界中医药

CSTPCDCHSSCD北大核心
影响因子：1.266
ISSN：1673-7202
年,卷(期)：2024.19(11)
  • 35